ADIPOQ and metabolic dysfunction-associated steatotic liver disease: Furthermore, data show that adiponectin impedes hepatic fibrosis, by inhibiting platelet-derived growth factor (PDGF) stimulation and downregulating the transforming growth factor beta 1 (TGF-β1) (26), whilst as NAFLD progresses, adiponectin levels appear to decline (27).